VRNA
- Verona Pharma plc
()
Overview
Company Summary
Verona Pharma plc (VRNA) is a pharmaceutical company that specializes in developing and commercializing innovative prescription medicines to treat respiratory diseases. The company is focused on addressing the unmet medical needs of patients suffering from chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
Verona Pharma primarily focuses on developing novel drugs that can effectively treat bronchoconstriction, inflammation, and mucus secretion associated with respiratory diseases. By targeting various pathways and mechanisms within the respiratory system, the company aims to provide improved treatment options for patients and enhance their quality of life.
The company's lead product candidate is called ensifentrine (formerly known as RPL554), which is a first-in-class inhaled small molecule dual phosphodiesterase (PDE) 3 and 4 inhibitor. Ensifentrine acts by relaxing the smooth muscles in the airways, reducing inflammation, and enhancing the clearance of mucus. It is being developed as both a maintenance treatment and a rescue therapy for COPD patients.
Verona Pharma seeks to differentiate itself by leveraging the potential of ensifentrine across multiple respiratory indications, including COPD, asthma, and cystic fibrosis. The company also collaborates with other research institutions and pharmaceutical partners to expand its product pipeline and explore additional therapeutic applications for its drug candidates.
In summary, Verona Pharma is a pharmaceutical company dedicated to developing innovative medicines targeting respiratory diseases, with a particular focus on COPD. Through its lead product candidate, ensifentrine, the company aims to provide new treatment options that can alleviate symptoms and improve the lives of patients suffering from respiratory disorders.